MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $9.50 (101.27% upside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetActions
1/19/2016BarclaysInitiated CoverageUnderweight$6.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015JPMorgan Chase & Co.Reiterated RatingNeutral$8.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2015Cowen and CompanyReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Goldman SachsBoost Price TargetNeutral$6.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2015William BlairReiterated RatingOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2015William BlairReiterated RatingOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2015JPMorgan Chase & Co.Initiated CoverageNeutral$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015BMO Capital MarketsSet Price TargetBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015HC WainwrightSet Price TargetBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2015HC WainwrightSet Price TargetBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/11/2014Credit SuisseDowngradeNeutral -> Underperform$8.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014Chardan CapitalReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Citigroup Inc.Reiterated RatingSell$7.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2014JMP SecuritiesLower Price TargetMarket Outperform$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2014Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2014Jefferies GroupReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2014JMP SecuritiesReiterated RatingMarket Outperform$10.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2014Jefferies GroupUpgradeHold -> Buy$8.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/26/2014BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2014HC WainwrightInitiated CoverageNeutral -> Buy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2014Goldman SachsReiterated RatingHold -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2014Citigroup Inc.Boost Price Target$5.50 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2014Maxim GroupUpgradeHold -> Buy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2014Chardan CapitalDowngradeBuy -> Neutral$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2014Jefferies GroupBoost Price Target$7.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/12/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha